Although antithrombotic options for supplementary prevention of venous thromboembolism (VTE) have already been evaluated in scientific trials, studies in major prevention of asymptomatic aPL-positive individuals
Although antithrombotic options for supplementary prevention of venous thromboembolism (VTE) have already been evaluated in scientific trials, studies in major prevention of asymptomatic aPL-positive individuals